Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 257

1.

A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.

Westra D, Wetzels JF, Volokhina EB, van den Heuvel LP, van de Kar NC.

Neth J Med. 2012 Apr;70(3):121-9. Review.

2.

Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases.

Nester CM, Brophy PD.

Curr Opin Pediatr. 2013 Apr;25(2):225-31. doi: 10.1097/MOP.0b013e32835df4a3. Review.

PMID:
23486421
3.

Atypical hemolytic uremic syndrome: from the rediscovery of complement to targeted therapy.

Fakhouri F, Frémeaux-Bacchi V, Loirat C.

Eur J Intern Med. 2013 Sep;24(6):492-5. doi: 10.1016/j.ejim.2013.05.008. Epub 2013 Jun 5. Review.

PMID:
23756030
4.

Posttransplant recurrence of atypical hemolytic uremic syndrome.

Valoti E, Alberti M, Noris M.

J Nephrol. 2012 Nov-Dec;25(6):911-7. doi: 10.5301/jn.5000146. Review.

PMID:
22760880
5.

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.

Köse O, Zimmerhackl LB, Jungraithmayr T, Mache C, Nürnberger J.

Semin Thromb Hemost. 2010 Sep;36(6):669-72. doi: 10.1055/s-0030-1262889. Epub 2010 Sep 23.

PMID:
20865644
6.

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations.

Alberti M, Valoti E, Piras R, Bresin E, Galbusera M, Tripodo C, Thaiss F, Remuzzi G, Noris M.

Am J Transplant. 2013 Aug;13(8):2201-6. doi: 10.1111/ajt.12297. Epub 2013 Jun 3.

7.

Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand.

Fox LC, Cohney SJ, Kausman JY, Shortt J, Hughes PD, Wood EM, Isbel NM, de Malmanche T, Durkan A, Hissaria P, Blombery P, Barbour TD.

Nephrology (Carlton). 2018 Jun;23(6):507-517. doi: 10.1111/nep.13234. Review.

PMID:
29419916
8.

Atypical hemolytic uremic syndrome.

Loirat C, Frémeaux-Bacchi V.

Orphanet J Rare Dis. 2011 Sep 8;6:60. doi: 10.1186/1750-1172-6-60. Review.

9.

Novel aspects of atypical haemolytic uraemic syndrome and the role of eculizumab.

Verhave JC, Wetzels JF, van de Kar NC.

Nephrol Dial Transplant. 2014 Sep;29 Suppl 4:iv131-41. doi: 10.1093/ndt/gfu235. Review.

PMID:
25165180
10.

Eculizumab in the treatment of Shiga toxin haemolytic uraemic syndrome.

Walsh PR, Johnson S.

Pediatr Nephrol. 2018 Jul 30. doi: 10.1007/s00467-018-4025-0. [Epub ahead of print] Review.

PMID:
30058046
11.

Haemolytic uraemic syndrome: an overview.

Amirlak I, Amirlak B.

Nephrology (Carlton). 2006 Jun;11(3):213-8. Review.

PMID:
16756634
12.

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

Wong EK, Goodship TH, Kavanagh D.

Mol Immunol. 2013 Dec 15;56(3):199-212. doi: 10.1016/j.molimm.2013.05.224. Epub 2013 Jun 28. Review.

13.

Systemic complement activation and complement gene analysis in enterohaemorrhagic Escherichia coli-associated paediatric haemolytic uraemic syndrome.

Ahlenstiel-Grunow T, Hachmeister S, Bange FC, Wehling C, Kirschfink M, Bergmann C, Pape L.

Nephrol Dial Transplant. 2016 Jul;31(7):1114-21. doi: 10.1093/ndt/gfw078. Epub 2016 May 4.

PMID:
27190382
14.

[Atypical hemolytic-uremic syndrome related to abnormalities within the complement system].

Frémeaux-Bacchi V, Fakhouri F, Roumenina L, Dragon-Durey MA, Loirat C.

Rev Med Interne. 2011 Apr;32(4):232-40. doi: 10.1016/j.revmed.2009.09.039. Epub 2011 Mar 3. French.

15.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyó JM, Macía M, Mendizábal S, Praga M, Román E, Torra R, Valdés F, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2015;35(5):421-47. doi: 10.1016/j.nefro.2015.07.005. Epub 2015 Oct 9. English, Spanish.

16.

An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document.

Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, Praga M, Torra R, Vilalta R, Rodríguez de Córdoba S.

Nefrologia. 2013 Jan 18;33(1):27-45. doi: 10.3265/Nefrologia.pre2012.Nov.11781. English, Spanish.

17.

Treatment and management of children with haemolytic uraemic syndrome.

Walsh PR, Johnson S.

Arch Dis Child. 2018 Mar;103(3):285-291. doi: 10.1136/archdischild-2016-311377. Epub 2017 Sep 12. Review.

PMID:
28899876
18.

STEC-HUS, atypical HUS and TTP are all diseases of complement activation.

Noris M, Mescia F, Remuzzi G.

Nat Rev Nephrol. 2012 Nov;8(11):622-33. doi: 10.1038/nrneph.2012.195. Epub 2012 Sep 18. Review.

PMID:
22986360
19.

Atypical haemolytic uraemic syndrome.

Kavanagh D, Goodship TH, Richards A.

Br Med Bull. 2006;77-78:5-22. Epub 2006 Sep 11. Review.

PMID:
16968692
20.

Haemolytic uraemic syndrome.

Kavanagh D, Goodship T.

Nephron Clin Pract. 2011;118(1):c37-42. doi: 10.1159/000320901. Epub 2010 Nov 11.

PMID:
21071971

Supplemental Content

Support Center